Bio Pharma Dive

MAY 1, 2024

Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.

Sales 306

Sales 306

Bio Pharma Dive

NOVEMBER 9, 2022

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 325

Sales Development Drugs 325

Bio Pharma Dive

APRIL 30, 2024

Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.

Sales 306

Sales Production Drugs 306

Bio Pharma Dive

DECEMBER 22, 2021

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness.

Sales 344

Sales FDA Approval Doctor Doctors 344

Bio Pharma Dive

NOVEMBER 7, 2024

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.

Sales 290

Sales Gene Therapy Gene Drugs 290

Bio Pharma Dive

NOVEMBER 3, 2022

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product.

Sales 306

Sales Vaccination Vaccine Production 306

Bio Pharma Dive

OCTOBER 30, 2024

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of its competing RSV shot.

Sales 290

Sales Vaccination Vaccine 290

Bio Pharma Dive

OCTOBER 28, 2021

But sales could climb even higher if it works as a preventive treatment too. Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 317

Sales Drugs 317

Bio Pharma Dive

JANUARY 6, 2023

The gene therapy developer will receive $95 million from Bristol Myers Squibb, slightly less than it got in the recent sale of another priority review voucher.

Sales 315

Sales Gene Therapy Gene Development 315

Bio Pharma Dive

NOVEMBER 2, 2023

The rival companies reported strong quarterly sales growth for their latest products, which could face off as weight loss treatments next year.

Sales 305

Sales Production Drugs 305

Bio Pharma Dive

JULY 27, 2022

A manufacturing issue for Breyanzi, meanwhile, impacted sales. Demand has increased faster than Bristol Myers can make Abecma, although the company said supply is improving.

Sales 298

Sales Production Manufacturing 298

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Sales 246

Sales Vaccination Vaccine Medicine 246

Bio Pharma Dive

JULY 21, 2021

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks. The pharmaceutical company expects $2.5

Sales 306

Sales Vaccination Vaccine Manufacturing 306

Bio Pharma Dive

OCTOBER 9, 2023

The purchase agreement with Chongqing Zhifei Biological Products is part of GSK’s plan to double sales of the shingles vaccine by 2026.

Sales 287

Sales Vaccination Vaccine Production 287

Bio Pharma Dive

JANUARY 31, 2024

The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.

Sales 286

Sales Vaccination Vaccine 286

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 290

Sales Medicine Drugs Marketing 290

Bio Pharma Dive

JANUARY 24, 2023

The drugmaker reported fourth quarter revenue that fell short of forecasts, but reiterated confidence in reaching a $60 billion pharmaceutical sales goal.

Sales 312

Sales Drugs 312

Bio Pharma Dive

MAY 2, 2024

First quarter sales of the in-demand obesity drug were down slightly compared to the fourth quarter last year, as the company tries to meet demand.

Sales 256

Sales Drugs 256

Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 246

Sales Marketing Production 246

Bio Pharma Dive

OCTOBER 18, 2021

The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines.

Sales 290

Sales Drugs Medicine 290

Pharmaceutical Technology

JANUARY 31, 2025

Roche achieved a sales growth of 7% (3% in CHF) in 2024, citing strong demand for pharmaceutical products.

Sales 233

Sales Production 233

Bio Pharma Dive

MAY 4, 2022

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.

Sales 279

Sales Vaccination Vaccine 279

Pharmaceutical Technology

MARCH 2, 2023

Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.

Sales 245

Sales Life Science Licensing Licensing 245

Bio Pharma Dive

AUGUST 17, 2022

The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their shots and therapeutics.

Sales 279

Sales Marketing Vaccination Vaccine 279

Pharmaceutical Technology

JULY 31, 2023

Pharma sales have undergone a seismic transformation after Covid-19, with the adoption of artificial intelligence tools.

Sales 246

Sales 246

Pharmaceutical Technology

FEBRUARY 3, 2023

Merck (MSD outside North America) has reported a 2% increase in worldwide sales to $13.83bn in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter. The company’s pharmaceutical sales recorded a 1% rise to $12.18bn compared to $12.03bn in the prior-year quarter. in the same quarter last year.

Sales 246

Sales Engineer Vaccination Vaccine 246

Bio Pharma Dive

FEBRUARY 3, 2022

Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.

Sales 279

Sales Doctors Doctor Drugs 279

Pharmaceutical Technology

AUGUST 9, 2024

Days after competitor Novo Nordisk posted underwhelming Wegovy sales, Eli Lilly cited “strong performance” for Zepbound and Mounjaro.

Sales 246

Sales Drugs 246

Bio Pharma Dive

JANUARY 13, 2025

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

Sales 317

Sales Vaccination Vaccine Marketing 317

Bio Pharma Dive

AUGUST 3, 2023

Sales of the company’s COVID-19 vaccine plummeted 94% year over year. But executives believe newer products can help revenue rebound.

Sales 246

Sales Vaccination Vaccine Production 246

Bio Pharma Dive

AUGUST 8, 2024

Company executives claimed “unprecedented demand” for the Duchenne gene therapy will soon cause a sales surge, countering a dip in quarterly sales and financial projections that raised concerns among investors.

Sales 200

Sales Gene Therapy Gene 200

Bio Pharma Dive

NOVEMBER 6, 2024

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ambitious sales target and Syndax inked a lucrative royalty deal.

Sales 162

Sales Vaccination Vaccine 162

Bio Pharma Dive

APRIL 2, 2024

Stalking horse bidder Merz Therapeutics could get rights to Acorda’s three marketed drugs if its $185 million proposal holds.

Sales 306

Sales Marketing Drugs 306

Bio Pharma Dive

JULY 1, 2024

The gene therapy developer, which cut jobs in October, expects the sale of a Lexington, Massachusetts, facility to Genezen to lower its cash burn.

Sales 189

Sales Gene Therapy Manufacturing Gene 189

Bio Pharma Dive

FEBRUARY 3, 2023

The biotech recently stopped a trial of its experimental conditioning regimen over safety concerns. Now it’s halting further development work as it undertakes a strategic review.

Sales 325

Sales Trials Development 325

Bio Pharma Dive

APRIL 18, 2023

Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

Sales 221

Sales Vaccination Vaccine Drugs 221

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 2, 2024

per cent growth in sales of generic medicines at Maximum Retail Price (MRP) value in the month of August, as compared to the sales same month a year […]

Sales 189

Sales Medicine Clinical Trials Clinical Trials 189